Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585697 | 0.96 | NAAA (0.36) | NAAASMN1; SMN2GAAMAPK1HTT | |
| SCHEMBL4586708 | 0.82 | NFKB1 (0.40) | GAANFKB1NFKB2KMT2ARELA | |
| SCHEMBL4586907 | 0.77 | NFKB1 (0.41) | GAANFKB1NFKB2KMT2ARELA | |
| SCHEMBL6285830 | 0.73 | NAAA (0.36) | NAAASMN1; SMN2GAAMAPK1HTT | |
| SCHEMBL4586036 | 0.70 | EPHX1 (0.46) | NAAASMN1; SMN2GAAMAPK1HTT | |
| SCHEMBL6285824 | 0.68 | RAB9A (0.39) | NAAASMN1; SMN2GAAMAPK1HTT | |
| SCHEMBL4585679 | 0.68 | EPHX1 (0.45) | NAAASMN1; SMN2GAAMAPK1HTT | |
| SCHEMBL4586822 | 0.67 | — | — | |
| SCHEMBL4585702 | 0.66 | OAT (0.31) | — | |
| SCHEMBL13387564 | 0.64 | GAA (0.59) | NAAASMN1; SMN2GAAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458669-A4 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | UNIV SYDNEY (AU) | 2008-10-29 | — | — | EP | disclosed |
| US-20050004083-A1 | Neurologically-active compounds | NEURO THERAPEUTICS LIMITED (AU) | 2005-01-06 | — | — | US | disclosed |
| EP-1458669-A1 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003045897-A1 | NEOROLOGICALLY-ACTIVE COMPOUNDS | UNIVERSITY OF SYDNEY (AU) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004083-A1 | Neurologically-active compounds | GABRA2, GABRA5, GABRE | NAAA 686/4885SMN1; SMN2 250/4885GAA 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.